Curioler — home
General
Tier 1 · Strong research evidence

Why this tier: Systematic review or meta-analysis

Systematic review

L-carnosine for autistic children: an early promise the later trials did not confirm

Published 14 September 2026 · 4 min read

15 reads

L-carnosine is a supplement sold to parents as a natural way to ease autism. The careful trials so far found it does not change autism itself. A few saw a small gain in one area, such as sleep or overactive behavior, but no second trial has found the same gain. A 2025 review of the trials found no solid proof that it helps.

What this research found

  • A 2025 review brought together 20 trials of antioxidant supplements in autism, including the carnosine trials. An antioxidant is a substance meant to protect the body's cells from a kind of wear called oxidative stress. The review's verdict on carnosine was that it "has no solid evidence of its clinical efficacy across the included trials." In plain words, there is no solid proof that it helps children.
  • The same review, when it described the trials one by one, listed carnosine among supplements linked to better social understanding and communication. Its overall verdict above is the one that weighs the trials together.
  • The largest trial had 70 children, all already taking risperidone, a prescription medicine often used in autism. Half also took 800 mg of carnosine a day for 10 weeks. The other half took a placebo, a dummy pill that looks the same. Neither the families nor the doctors knew who had which.
  • That trial was built mainly to test irritability: outbursts and getting upset quickly. Carnosine made no difference to it. It also made no difference to low energy, repeated movements, or speech that is repetitive or out of place. The one thing that improved more than with the placebo was overactive behavior and not following instructions.
  • In a trial of 43 children taking 500 mg a day, carnosine did not change how severe their autism was rated. It did help sleep. The children were less sleepy during the day, had fewer unusual events in their sleep (such as sleepwalking or night terrors), and scored better on sleep problems overall.
  • In a trial of 63 children (32 took carnosine, 31 took a placebo), autism ratings and a sleep questionnaire showed no change bigger than chance alone would explain. The only exception was a single item on the autism rating, called "intellectual response".
  • A small 2024 trial tested children's blood and confirmed that carnosine does get into the body. Even so, it found no difference on anything it measured. Its authors concluded that carnosine did not work for managing autism in children.
  • One possible reason comes from a separate trial. Carnosine did not change the blood markers of oxidative stress, the very cell wear it is supposed to reduce. So the idea behind it may never reach the brain as any real change.

What this means for caregivers

  • If you are hoping carnosine will help with autism itself, meaning how your child connects and communicates or their repeated behaviors, the careful trials do not support that hope.
  • The one result that comes up more than once, in some form, is sleep. If sleep is what worries you most, raise it with your pediatrician. They can check the more common causes of poor sleep first.
  • Children in these trials generally coped well with carnosine. So the main costs are money and effort, not health. But safe is not the same as working.
  • Nothing here suggests swapping therapy or prescribed medicine for a supplement. The review says plainly that antioxidants are not justified as a treatment on their own.
  • Tell your child's doctor about any supplement you start, including ones bought over the counter, so it can be tracked alongside everything else.

Important caveats

  • Carnosine is often sold on the back of an early trial, from 2002, that reported gains in language and behavior. The larger, more careful trials since then have not found the same thing, and they are the better guide.
  • Not finding proof is not the same as proving it does nothing. These trials were small and short. A modest benefit for some children could still have been missed.
  • The trials used very different doses, some several times higher than others. None worked out what dose, if any, would help.
  • The good results that do appear are single measures in single trials. Treat each one as a question still to be tested, not an answer.
  • Supplements are checked far less strictly than medicines. What is on the label may not match what is in the bottle.

The science behind it

This part is written for researchers, so it gets technical. Reading it anyway is what researchers do: checking how a finding was reached, not just what it says. It’s slow going at first and gets easier after your first few articles. Skipping it is fine too.

A 2025 systematic review of 20 antioxidant trials in autism found the L-carnosine studies contradictory and at high risk of bias, with no solid evidence of clinical benefit. The individual randomized trials mostly missed their main targets: no change in autism severity or irritability, with scattered improvements in single areas such as sleep quality or hyperactivity that no second trial has confirmed.

At a glance

Sample size: Systematic review of 20 antioxidant trials; the L-carnosine randomized trials within it enrolled 43, 63 and 70 children, with a further 2024 pilot trial
Demographics: Autistic children roughly aged 3-12, across trials in Iran, India and elsewhere; most trials ran 8 to 10 weeks
Key outcome: No trial showed a reliable improvement in core autism symptoms. The largest (70 children, 800 mg/day added to risperidone for 10 weeks) missed its primary target of irritability entirely, improving only hyperactivity/non-compliance. The review concludes there is no solid evidence of clinical efficacy for carnosine.
Methodology: A PROSPERO-registered systematic review searched PubMed, Scopus, ClinicalTrials.gov and Cochrane-Ovid, included 20 antioxidant trials in autism and assessed them with the Cochrane Risk-of-Bias tool. Its L-carnosine findings are read here alongside the underlying randomized, double-blind, placebo-controlled trials and a 2024 pilot trial that also measured carnosine levels in blood.
Researchers: D. A. Abraham, Z. Mehrazad-Saber, S. Kheirouri, R. Hajizadeh-Zaker, S. Akhondzadeh, M. G. Rajanandh
Institutes: Journal of Autism and Developmental Disorders (PROSPERO CRD42023490581), Tehran University of Medical Sciences, Roozbeh Hospital, SRM College of Pharmacy, India (CTRI/2019/07/020102)

Limitations:

  • Trials are small (43 to 70 children) and short, typically 8 to 10 weeks
  • Doses varied widely (500 mg/day, 800 mg/day, 10-15 mg/kg), so the trials are not directly comparable and a dose effect cannot be ruled out
  • The review judged the antioxidant trials overall to carry a high risk of bias
  • The scattered positive findings are single subscales in single trials, unreplicated: the pattern you would also expect from chance
  • Including very young children risks mistaking normal developmental progress for a treatment effect

About this research

The anchor source is a 2025 PROSPERO-registered systematic review (CRD42023490581) in the Journal of Autism and Developmental Disorders, which searched four databases, included 20 antioxidant trials in autism and applied the Cochrane Risk-of-Bias tool. It is read here against the primary randomized, double-blind, placebo-controlled carnosine trials it covers and a 2024 registered pilot trial that measured plasma carnosine directly. The evidence base is real but thin: a handful of small, short trials with inconsistent dosing and a high risk of bias.

The trials in their own terms. The findings above are written without the names of the scales and outcomes. Here they are, so you can match them to the papers:

  • The review: in its qualitative synthesis (the trial-by-trial description), L-carnosine was classed as showing improvement in social cognition and communication; its conclusion across the included trials was no solid evidence of clinical efficacy.
  • 70 children, 800 mg/day with risperidone, 10 weeks: irritability was the primary outcome, the one result the trial was designed to test, and it did not differ significantly from placebo. Lethargy, stereotypic behavior and inappropriate speech also did not; only hyperactivity/non-compliance improved more than placebo.
  • 43 children, 500 mg/day: no change in autism severity on the GARS-2 (Gilliam Autism Rating Scale, Second Edition); significant reductions in daytime sleepiness, parasomnias and total sleep disorder scores.
  • 63 children (32 carnosine, 31 placebo): no statistically significant improvement on the CARS2-ST (Childhood Autism Rating Scale, Second Edition, Standard Version) or the BEARS sleep screen, apart from the single "intellectual response" item.
  • 2024 pilot trial: plasma carnosine rose after supplementation, with no significant difference on any outcome measure.
  • Mechanism: a separate trial found carnosine did not shift oxidative-stress markers.

Sources

Related topics

This summary was prepared by the Curioler research agent. It is not medical advice. Always consult a qualified professional before making decisions about your child's care.

Reviewed by Bhavin Solanki, caregiver parent. This is informational content, not medical advice — see our disclaimer.